ClinicalTrials.gg
RecruitingNCT06980480Updated Oct 13, 2026

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

A Phase 3 interventional study of IGI, 10% in Multiple Myeloma and Secondary Immunodeficiency, sponsored by Takeda. Recruiting at 65 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 13, 2026First site in Israel9 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Multiple Myeloma by Takeda — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Myeloma · Takeda.

Planned enrollment
9th of 38
183 · median 61
Started
2026
the only one that year
Phase 3
11 of 54
1 open now
Registered
54th of 54
by date

Among the 54 studies in Multiple Myeloma by Takeda, this one is the 9th largest by planned enrollment of the 38 interventional ones that give a count, is the only one that started in 2026, is one of 11 in phase 3, and was the 54th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 54 studies in Multiple Myeloma by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Multiple Myeloma by Takeda, or all of them as a file.
02

Study summary

Multiple myeloma is a cancer of the plasma cells in the bone marrow.

The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy.

Participants will be randomly assigned to one of two groups:

  1. Primary infection prevention group: They will receive IGI, 10% for 12 months.
  2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period.

During the study, participants will visit their study clinic 15 times (for 4-week dosing interval) or 19 times (for 3-week dosing interval) and their total participation duration will be up to 14 months (including screening period approximately 8 weeks).

03

Conditions studied

  • Multiple Myeloma
  • Secondary Immunodeficiency

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participants must have a documented diagnosis of Multiple Myeloma (MM) according to the guidelines by the International Myeloma Working Group (IMWG) before enrollment.
  2. Participant who recently started teclistamab monotherapy within the first 8 weeks of their planned treatment schedule and are planned to receive teclistamab for the next 12 months.
  3. The participant has provided (that is, in writing, documented via a signed and dated Informed Consent Form [ICF]) and any required privacy authorization before the initiation of any study procedures.
  4. The participant is at least 18 years of age at the time of signing the ICF.
  5. If a person of engages in sexual relations that carry risk of pregnancy, they agree to the following for the period from screening until 30 days after the last dose of study drug:

    1. To use a highly effective method.
    2. To avoid donating ova.

Exclusion criteria

Exclusion Criteria:

  1. The participant has not achieved at least a minimal response to teclistamab during the screening period after signing the ICF and within 8 weeks of the first step-up dose of teclistamab.
  2. The participant has a current serious infection or greater than (>) 1 serious infection in the past 3 months before screening.
  3. The participant has a documented polyclonal IgG level less than (\<) 150 milligrams per deciliter (mg/dL) at the most recent assessment before teclistamab initiation (within 4 weeks) as assessed by the investigator according to the site's standard practice.
  4. The participant is currently receiving immunoglobulin products or has received immunoglobulin products within 16 weeks before screening.
  5. The participant has received a hyperimmune or specialty high-titer immunoglobulin product (example, cytomegalovirus immune globulin, varicella-zoster immune globulin, immune globulin) within 30 days before screening.
  6. The participant has received live viral vaccines within 30 days before screening.
  7. The participant has an performance status score of >2.
  8. The participant has an active viral or bacterial infection or symptoms/signs of such an infection requiring treatment with anti-infectives within 1 week before enrollment.
  9. The participant has received other B Cell Maturation Antigen (BCMA)*Cluster of Differentiation (CD3)-directed Bispecific Antibody therapy (BsAb), BCMA-targeted chimeric antigen receptor T-cell (CAR T-cell), or BCMA-targeted antibody drug conjugate (ADC) therapy within 1 year prior to screening.
  10. The participant is scheduled to undergo plasmapheresis during the course of study or has undergone plasmapheresis in the last 16 weeks before screening.
  11. The participant may be excluded from the study if, in the opinion of the investigator, the participant is at high risk for symptomatic hyperviscosity syndrome.
  12. The participant has major surgery scheduled during the study, or the participant has not fully recovered from a recent major surgery (as judged by the investigator) during screening (participants with planned surgical procedures to be conducted under local anesthesia may participate).
  13. The participant has an active secondary (non-MM) or other medical condition with life-expectancy of less than (\<) 2 years.
  14. The participant has a known history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) after Intravenous Immunoglobulin (IVIG) and/or immune serum globulin infusions.
  15. The participant has a known history or current diagnosis of thromboembolic episodes such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, , peripheral artery disease within 6 months before screening.
  16. The participant has moderate to severe renal dysfunction based on an estimated less than (\<) 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2), as defined by kidney disease: Improving Global Outcomes Clinical Practice Guideline for the Management of Glomerular Diseases, 2021 at the time of screening.
  17. The participant has a known history of or is positive at screening for one or more of the following: hepatitis B surface antigen, Polymerase Chain Reaction (PCR) for virus, PCR for (HIV) Type 1 and Type 2. Cured participants with a history of hepatitis C infection who have a negative PCR test at screening are eligible.
  18. The participant has a documented diagnosis of a form of primary immunodeficiency (PID) involving a defect in antibody formation and requiring IgG replacement, as defined according to the International Union of Immunological Societies Committee.
  19. The participant has a persistent serum and alanine aminotransferase >3.0 times the (ULN) at screening (may be repeated once to determine if it is persistent).
  20. The participant has an immunoglobulin A (IgA) deficiency (\<0.07 grams per liter [g/L]) with antibodies to IgA and a history of hypersensitivity reaction to IVIG.
  21. Participant with a known systemic hypersensitivity to any of the of IGI, 10% in accordance with the investigator's brochure/package insert/Summary of Product Characteristics.
  22. Known substance abuse including opiates, psychostimulant agents, or other illicit drugs with the exception of cannabinoids within 12 months of screening.
  23. The participant has anemia that would preclude phlebotomy for laboratory studies, according to standard practice at the site, at the discretion of the investigator (may be repeated once to determine if it has resolved).
  24. The participant has a medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with the successful completion of the study or place the participant at undue medical risk.
  25. The participant is receiving treatment (other than for MM or ) at screening or plans to receive immunosuppressive treatment after study enrollment.
  26. The participant is not willing and able to comply with the protocol requirements.
  27. The participant has participated or is scheduled to participate in another clinical study involving an product (IP) or investigational device within 30 days before screening and during the course of the study.
  28. The participant is a family member or employee of the investigator or the investigator's site staff.
  29. The participant is pregnant or has a positive pregnancy test or is lactating at the time of screening or enrollment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
183 participants (estimated)

Study arms

  • Experimental
    Primary Infection Prophylaxis: IGI, 10%

    Participants randomized to primary infection prophylaxis will receive a 400 milligrams per kilogram (mg/kg) dose of IGI, 10% in accordance with the standard of care (SOC), intravenously (IV) every 3 or 4 weeks within 3 days after randomization up to 12 months.

    Biological: IGI, 10%

  • Active comparator
    Secondary Infection Prophylaxis: IGI, 10%

    Participants randomized to secondary infection prophylaxis will receive a 400 mg/kg dose of IGI, 10% in accordance with the SOC, IV every 3 or 4 weeks only after experiencing at least one serious infection, as determined by the investigator, for the remainder of the 12 months observational period.

    Biological: IGI, 10%

Interventions

  • BiologicalIGI, 10%

    IGI, 10% IV infusion.

    Also known as: TAK-339, Gammagard Liquid, KIOVIG

06

What researchers measure

Primary outcomes

  1. Time To the First Serious Infection

    Time frame: Up to 12 months

Secondary outcomes

  1. Number of Participants With at Least 1 Serious Infection

    Time frame: Up to 12 months

  2. Annualized Rate of Days on Antibiotics for Treatment of Bacterial Infections

    Time frame: Up to 12 months

  3. Annualized Rate of Bacterial Infections

    Time frame: Up to 12 months

  4. Annualized Rate of Serious Infections

    Time frame: Up to 12 months

  5. Annualized Rate of Acute Serious Bacterial Infections (ASBIs)

    Time frame: Up to 12 months

  6. Number of Participants With Any Infections

    Time frame: Up to 12 months

  7. Duration of Infections

    Time frame: Up to 12 months

  8. Time To Any First Infection

    Time frame: Up to 12 months

  9. Annualized Rate of Any Infections

    Time frame: Up to 12 months

  10. Number of Participants With Bacterial/Viral Infection/Fungal Infection

    Number of participants with bacterial/viral infection, including covid/fungal infection diagnosed clinically and via microbiology (culture, polymerase chain reaction \[PCR\], other imaging will be reported.

    Time frame: Up to 12 months

  11. Annualized Rate of Episodes of Fever due to Infections

    Time frame: Up to 12 months

  12. Total Immunoglobulin G (IgG) Levels in Serum

    Time frame: 3-Week dosing: Day 1 up to Day 357; 4-Week dosing: Day 1 up to Day 364

  13. IgG Subclasses (IgG1, IgG2, IgG3, and IgG4) Levels in Serum

    Time frame: 3-Week dosing: Day 1 up to Day 357; 4-Week dosing: Day 1 up to Day 364

  14. Antigen-specific Antibody Levels in Serum

    Time frame: 3-Week dosing: Day 1 up to Day 357; 4-Week dosing: Day 1 up to Day 364

  15. Number of Participants With Adverse Event (AEs) and Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 12 months

  16. Number of Participants With TEAEs Related to IGI, 10%

    Time frame: Up to 12 months

  17. Number of Participants With TEAEs Temporally Associated to the IGI, 10% Within 72 hours of Administration

    Time frame: Within 72 hours of IGI, 10% administration (up to 12 months)

  18. Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions due to TEAEs Related to IGI, 10%

    Time frame: Up to 12 months

  19. Number of Participants With at Least 1 Hospitalization due to Infection

    Time frame: Up to 12 months

  20. Number of Hospitalizations, Including Intensive Care Unit (ICU) and Non-ICU due to Infection

    Time frame: Up to 12 months

  21. Number of Participants With Outpatient Visits, Including Emergency Room (ER) Visits due to Infection

    Time frame: Up to 12 months

  22. Duration of Hospitalizations, Including ICU and Non-ICU due to Infection

    Time frame: Up to 12 months

  23. Number of Days of Hospitalization per Participant-year, Including ICU and Non-ICU due to Infection or Other Reasons

    Time frame: Up to 12 months

07

Study locations

65 of 65 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2028, 31 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 31 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 20, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Sep 11, 2028
CompletionEst.
Sep 11, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in Israel
Show 9 added (2 Australia, 2 Norway, 2 Romania, 1 Brazil, 1 Hungary, 1 Israel)
  • Greenslopes Private Hospital · Greenslopes, Australia
  • Royal Adelaide Hospital · Adelaide, Australia
  • Centro de Hematologia e Oncologia (CHO) · Joinville, Brazil
  • University of Debrecen DEOEC · Debrecen, Hungary
  • Shaare Zedek Medical Center · Jerusalem, Israel
  • Helse Nord-Troendelag Thrust · Levanger, Norway
  • Akershus University Hospital · Lorenskog, Norway
  • Institutul Clinic Fundeni · Bucharest, Romania
  • Coltea Clinical Hospital · Bucharest, Romania
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    9 sites added — first site in Israel
    Show 9 added (2 Australia, 2 Norway, 2 Romania, 1 Brazil, 1 Hungary, 1 Israel)
    • Greenslopes Private Hospital · Greenslopes, Australia
    • Royal Adelaide Hospital · Adelaide, Australia
    • Centro de Hematologia e Oncologia (CHO) · Joinville, Brazil
    • University of Debrecen DEOEC · Debrecen, Hungary
    • Shaare Zedek Medical Center · Jerusalem, Israel
    • Helse Nord-Troendelag Thrust · Levanger, Norway
    • Akershus University Hospital · Lorenskog, Norway
    • Institutul Clinic Fundeni · Bucharest, Romania
    • Coltea Clinical Hospital · Bucharest, Romania
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06980480
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jan 14, 2026
Primary completion
Sep 11, 2028 (estimated)
Completion
Sep 11, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion